The COVID years left Moderna with a large cash reserve. That's the cushion funding the rebuild.
↓ scroll to read
✦ The bottom line
Moderna's 2025 net loss was $2.8B, with revenue far below its spending. The crucial difference from other spicy names: Moderna banked enormous cash during the COVID boom, so it can fund years of losses without desperate fundraising. The risk isn't running out tomorrow — it's the cash pile eroding before the pipeline pays off.
↓ the brief below
✦ Teach me
Why the cash cushion changes the risk
For most pre-profit companies, the scary number is runway — how long until the cash runs out and they must raise more (diluting owners) or fold. Moderna is unusual: COVID left it with a multi-billion-dollar reserve, so it can absorb big losses for years on its own terms.
That doesn't make the losses harmless. A shrinking cash pile is a clock — just a slower one. The question becomes whether the pipeline delivers before the cushion gets uncomfortably thin.
Wall Street calls this
Cash reserves / runway
A well-funded money-loser is a fundamentally different (and lower) risk than a cash-strapped one. Moderna is buying *time* with its war chest — the bet is whether it buys *enough*.
Net loss · fiscal year 2025
−$2.8
B
Heavy R&D spending against shrunken revenue. Funded largely from the cash reserves built during the COVID years — which is why Moderna can run at this loss without constant fundraising.
Source · 10-K · Consolidated Statements of Operations · FY2025 · Filed Feb 20, 2026
⚠
Funded, but a clock
Large losses, but a COVID-built cash cushion funds years of rebuilding. Lower near-term risk than cash-strapped peers — the watch-item is whether the pipeline pays off before the reserve thins.
You just finished
Chapter 2 · FINANCIAL HEALTH
Losing Billions — But Funded
you now read: real cash left over (free cash flow)